CALIGAN PARTNERS LP 13F Portfolio
CALIGAN PARTNERS LP runs CALIGAN PARTNERS LP and currently holds 28 stock positions, which is fewer than the average of 231 among the investors we track. The portfolio is valued at approximately $2.13B. Their top holdings are LQDA, RVMD, ABVX, PCVX, EXEL. The top five represent 67.5% of reported portfolio weight. CALIGAN PARTNERS LP ranks #6 out of 1000 investors tracked by Alpha Score. In the most recent quarter, CALIGAN PARTNERS LP initiated 2 new positions. They added to 6 existing positions. They trimmed 2 positions. Their current best-performing preview position is LQDA with returns of +111.26%.
Portfolio Value
$2.13B
Alpha Score
428.3
#6 of 1000
Holdings
28
CALIGAN PARTNERS LP Current 13F Holdings
Reported holdings from CALIGAN PARTNERS LP's latest SEC 13F filing, ranked by portfolio weight.
28 stock holdings
| Holding | Weight | Avg Buy | Current | Return | Quarter Change |
|---|---|---|---|---|---|
 LQDA LIQUIDIA CORPORATION | 30.45% | $6.98 | $27.38 | +292.26% | Held |
 RVMD REVOLUTION MEDICINES INC | 17.28% | $78.48 | $189.76 | +141.79% | Added +18.69% |
 ABVX ABIVAX SA | 9.77% | $15.51 | $88.15 | +468.34% | Added +6.57% |
 PCVX VAXCYTE INC | 5.99% | $48.79 | $71.38 | +46.30% | Added +6.21% |
 EXEL EXELIXIS INC | 3.98% | $21.13 | $59.86 | +183.29% | Held |
 TNGX TANGO THERAPEUTICS INC | 3.68% | $9.68 | $23.81 | +145.97% | Added +3.79% |
 XENE XENON PHARMACEUTICALS INC | 2.53% | $51.40 | $36.44 | -29.11% | Trimmed -36.11% |
 ADMA ADMA BIOLOGICS INC | 2.25% | $12.11 | $10.36 | -14.45% | Added +20.36% |
 LBRX LB PHARMACEUTICALS INC | 2.20% | $24.66 | $37.22 | +50.93% | Held |
 IMCR IMMUNOCORE HLDGS PLC | 2.06% | $31.75 | $29.39 | -7.43% | New Buy |
Showing 1-10 of 28